trending Market Intelligence /marketintelligence/en/news-insights/trending/cwoxnuhypiol1bdxbzpniq2 content esgSubNav
In This List

Novartis, Pear Therapeutics to develop digital therapies for MS, schizophrenia

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Novartis, Pear Therapeutics to develop digital therapies for MS, schizophrenia

Novartis AG and Pear Therapeutics Inc. are partnering to develop software applications designed to treat disease and boost clinical results for patients with schizophrenia and multiple sclerosis.

Swiss drugmaker Novartis will collaborate with San Francisco-based Pear Therapeutics to advance the development of a digital therapeutic called Thrive for patients with schizophrenia. The therapy has shown potential usability, retention and preliminary effectiveness in early clinical studies.

The companies will also jointly design a new therapeutic app for patients with multiple sclerosis.

The partnership further supports the clinical viability of prescription digital therapeutics as an emerging treatment, said Pear President and CEO Corey McCann.

Schizophrenia is a mental disorder that affects an individual's social behavior and understanding of reality. Multiple sclerosis, meanwhile, is a disease that affects the central nervous system and disrupts the flow of information between the brain and body.

Pear Therapeutics develops digital therapies and drug/software combinations to behavioral health disorders. Pear's prescription digital therapeutics are designed to deliver treatments, such as cognitive behavioral therapy, to patients through mobile and desktop applications. Once approved, they may be prescribed alongside drug therapies and could also be used in the development of treatments for various diseases.